The Technical Analyst
Dynavax Technologies Corp [DVAX]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Dynavax Technologies Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.36% $11.21
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 464.19 mill |
| EPS: | -0.0500 |
| P/E: | -224.20 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 130.62 mill |
| Avg Daily Volume: | 1.972 mill |
| RATING 2024-04-26 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -224.20 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -4.69x |
| Company: PE -224.20 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 10.90 - 11.53 ( +/- 2.81%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-29 | Slebir John L | Sell | 0 | Common Stock |
| 2024-03-29 | Slebir John L | Sell | 300 000 | Stock Option (Right to Buy) |
| 2024-03-29 | Slebir John L | Sell | 80 000 | Stock Options (Right to Buy) |
| 2024-03-29 | Slebir John L | Sell | 50 000 | Restricted Stock Unit |
| 2024-03-29 | Slebir John L | Sell | 88 000 | Stock Options (Right to Buy) |
| INSIDER POWER |
|---|
| -33.92 |
| Last 100 transactions |
| Buy: 1 153 769 | Sell: 2 721 592 |
Forecast:
16:00 - $11.20
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $11.20
Forecast 2: 16:00 - $11.20
Forecast 3: 16:00 - $11.20
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $11.21 (0.36% ) |
| Volume | 1.550 mill |
| Avg. Vol. | 1.972 mill |
| % of Avg. Vol | 78.63 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DVAX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $12.92 | N/A | Active |
|---|
DVAX
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Latest Press Releases
2024-04-24 16:05:00 - Press Release
Dynavax To Report First Quarter 2024 Financial Results And Host Conference Call On May 8, 2024
Emeryville, calif. , april 24, 2024 /prnewswire/ -- dynavax technologies corporation (nasdaq: dvax), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on wednesday, may 8, 2024, after the u.s. financial markets close.
2024-02-27 18:54:00 - Press Release
Dynavax To Present At Td Cowen's 44th Annual Health Care Conference
Emeryville, calif. , feb. 27, 2024 /prnewswire/ -- dynavax technologies corporation (nasdaq: dvax), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the company will present at td cowen's 44th annual health care conference on monday, march 4 at 10:30 a.m.
2024-02-22 16:01:00 - Press Release
Dynavax Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Full Year 2024 Financial Guidance
Heplisav-b ® 2023 net product revenue grew 69% year-over-year to $213 million achieved market leader status in key segments retail pharmacy and idns in 2023 2024 heplisav-b net product revenue expected to be $265 - $280 million cash position increased to $742 million at year end and expect to be cash flow positive for full year 2024 conference call today at 4:30 p.m. et/1:30 p.m.
2024-02-08 16:15:00 - Press Release
Dynavax To Report Fourth Quarter And Full Year 2023 Financial Results And Host Conference Call On February 22, 2024
Emeryville, calif. , feb. 8, 2024 /prnewswire/ -- dynavax technologies corporation (nasdaq: dvax), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2023 financial results on thursday, february 22, 2024, after the u.s. financial markets close.
2024-01-08 09:00:00 - Press Release
Dynavax Announces Preliminary Unaudited Fourth Quarter And Full Year 2023 Financial Highlights
Preliminary full year 2023 heplisav-b ® vaccine net product revenue of approximately $213 million, a 69% year-over-year increase significant gains in heplisav-b market share in key market segments, with total u.s. market share increasing to approximately 44% compared to approximately 35% at the end of 2022 strengthened financial position with cash, cash equivalents and marketable securities at year end increasing to approximately $742 million; expects to be cash flow positive for full year 2024 emeryville, calif. , jan. 8, 2024 /prnewswire/ -- dynavax technologies corporation (nasdaq: dvax), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced preliminary, unaudited financial highlights for the fourth quarter and full year ended december 31, 2023.
Latest News
2024-03-24 07:39:48 - Seeking Alpha
Dynavax Technologies: Still A Believer
Dynavax's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23, making the company cash flow positive. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with Heplisav potential sales reaching $400 million by FY27. Dynavax's stock has been trading at the lower end of its range, but with positive prospects and a strong balance sheet, it presents a solid long-term investment opportunity.
2024-02-22 19:34:06 - Seeking Alpha
Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript
2024-02-22 18:16:06 - Zacks Investment Research
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
Dynavax Technologies (DVAX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.45 per share a year ago.
2024-01-05 10:34:42 - Zacks Investment Research
Dynavax Technologies (DVAX) Is a Great Choice for 'Trend' Investors, Here's Why
Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
2024-01-03 18:33:00 - PRNewsWire
Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
EMERYVILLE, Calif. , Jan. 3, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 42nd Annual J.P.
2024-01-02 13:53:27 - Seeking Alpha
Dynavax Technologies: Still A Solid Pick For 2024
Today, we take another look at Dynavax Technologies Corporation, which experienced a boost in revenue from the Covid pandemic, but this has now nearly completely diminished. However, the company's core asset is the HEPLISAV-B, a vaccine for Hepatitis B, which has gained market share and achieved high compliance rates. Third quarter results showed strong performance for HEPLISAV-B, leading to an increase in sales guidance for 2023. Analysts also expect a rebound in earnings and sales in 2024.
2023-12-18 10:31:34 - Zacks Investment Research
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
2023-11-22 09:46:24 - Zacks Investment Research
5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.
2023-11-20 17:04:00 - PRNewsWire
Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference
EMERYVILLE, Calif. , Nov. 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 4:40 p.m.
2023-11-07 11:17:30 - Zacks Investment Research
Is Dynavax Technologies (DVAX) Outperforming Other Medical Stocks This Year?
Here is how Dynavax Technologies (DVAX) and Cardinal Health (CAH) have performed compared to their sector so far this year.